3D Tissue Models

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2009 Technological Advancements in Radiation Oncology. Seminars in Radiation Oncology 19(3): 179-186, 2009.
2. 2009 Molecular Advances of Brain Tumors in Radiation Oncology Seminars in Radiation Oncology 19(3):171-178, 2009
3. 2009 Molecular Profiling in Glioblastoma: Prelude to Personalized Treatment Curr Oncol Rep. 11(1):53-61, 2009
4. 2009 Prognostic value of surviving in locally advanced prostate cancer: a Study based on RTOG 8610. Int J. Radiat Oncol Biol Phys. 73(4):1033-1042, 2009.
5. 2009 In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016 Clin Cancer Res 15(2):607-612
6. 2008 Overcoming therapeutic resistance in malignant gliomas: current practices and future directions Cancer Treat Res. 2008; 139: 173-189
7. 2008 The added value of concurrently-administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J. Neurooncol. 2008 May;88(1):43-50
8. 2008 Detection of EGFRvIII in routinely processed GBM clinical samples Clin Ca Res 2008; 14(2): 488-493
9. 2008 Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole brain radiotherapy with or without thalidomide on RTOG 0118 Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):71-8.
10. 2008 Phase III Study of Conventional Radiation Therapy Plus Thalidomide versus Conventional Radiation Therapy for Multiple Brain Metastasis Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86
11. 2008 Novel Radiation Enhancing Agents in Malignant Gliomas Radiosurgery 2008
12. 2008 The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the RTOG Radiat Oncol 3(32), 2008
13. 2008 Overcoming therapeutic resistance in malignant gliomas: current practices and future directions Cancer Treat Res. 139:173-189, 2008.
14. 2008 Biomarkers of clinical responsiveness in brain tumor patients: progress and potential Mol Diagn Ther 12(4): 199-208, 2008.
15. 2007 Chemoradiotherapy in malignant glioma: standard of care and future directions J. Clin Oncol 2007; 25(26): 4127-4136
16. 2007 The prognostic value of p16 in locally-advanced prostate cancer: a report from RTOG 9202 J. Clin Oncol 2007; 25(21): 3082-3089
17. 2007 Molecular and genetic profiling in human gliomas. Disc Med 7(38): 75-81, 2007
18. 2007 The Impact of Molecular Profiling on Clinical Trial Design in Glioblastoma Curr Oncol Rep. 2007 Jan;9(1):71-9.
19. 2006 Advancement of CNS Targeted Agents Combined with Radiation. Radiation Oncology Advances 2006
20. 2006 A phase II study of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1422-8
21. 2006 A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA as a mitogen in glioblastoma. Cancer Res . 2006 Nov 15;66(22):10815-23
22. 2006 Interpretation of molecular marker data in the modern era. Int J. Radiat. Oncol. Biol. Phys. 2006; 66(1):1-2
23. 2006 A phase II study of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023 Int J of Radiat Oncol Biol Phys 2006; 65(5):1422-1428.
24. 2006 A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA as a mitogen in glioblastoma Cancer Res 2006; 66(22): 10815-10823
25. 2006 Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplasticglioma? Crit Rev Oncol Hematol. 2006 Nov;60(2):99-111.
26. 2006 Radiation Enhancing Agents for Tumors of the Central Nervous System Semin Radiat Oncol. 2006 Jan;16(1):29-37
27. 2006 Predictive and prognostic markers in prostate cancer Curr Cancer Ther Rev. 2006 Nov;7(6):490-504
28. 2006 Radiation-induced RhoA activation increases cellular invasion and motility of glioblastoma cells via IGFR/AKT-dependent signaling J. Neurooncol, 2006 Feb;76(3):227-37.
29. 2006 Temozolomide-mediated radiation enhancement in gliomas: a report on underlying mechanisms Clin Ca Res 2006; 12(15):4738-4746
30. 2005 Immunohistochemically-Determined Total Epidermal Growth Factor Receptor (EGFR) Levels are not of Prognostic Value in Newly-Diagnosed Glioblastoma Multiforme (GBM): A Report from the Radiation Therapy Oncology Group (RTOG). Int J. Rad Oncol Biol Phys. 2005 Jun 1; 62(2):318-327
31. 2005 Survivin mediates resistance to antiandrogen therapy in prostate cancer Oncogene 2005 Apr 7; 24(15): 2474-2482
32. 2005 Results of Whole- Brain Radiation as Salvage of Methotrexate Failure in Patients with Primary Central Nervous System Lymphoma. J Clin Oncol 2005 Mar 1; 23(7):1507-1513.
33. 2005 Adenovirus-mediated Inhibition of Survivin Expression Sensitizes Human Prostate Cancer Cells to Paclitaxel In Vitro and In Vivo. Prostate 2005 Aug 1;64(3):293-302
34. 2005 Cellular and genetic changes in malignant gliomas following irradiation in patients requiring early reresection of progressive tumor J. Neurooncol 2005 Sept;74(2):151-4
35. 2005 Expression of the Epidermal Growth Factor Receptor (EGFR) is Associated with Improved Outcome in Muscle-Invading Bladder Cancer Int J. Rad Oncol Biol Phys. 2005 Jun 1; 62(2): 309-317.
36. 2005 Prostate Cancer Biomarkers. Oncogenomics. Humana Press, 2005
37. 2005 Brachytherapy for CNS Neoplasms Brachytherapy. Lippincott, 2005.
38. 2004 Survivin Enhances Radiation Resistance in Primary Human Glioblastoma Cells via Caspase-Independent Mechanisms. Oncogene. 2004 Sep 30;23(45):7494-506
39. 2004 The contribution of Epidermal Growth Factor Receptor (EGFR) signaling pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data 1. Int J Rad Onc Biol Phys 2004; 58(3): 927-931.
40. 2004 Molecular and genetic markers in gliomas of prognostic value Cancer of the Central Nervous System (Second Edition: editors: Black, P.McL. and Loeffler, J.S.) Lippincott Williams and Wilkins, 2004
41. 2004 The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas J Clin Oncol 2004 May 15;22(10):1926-33
42. 2004 The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects J Neurooncol. 2004 Mar-Apr;67(1-2):177-88
43. 2003 Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from RTOG 86-10. J Clin Oncol 2003
44. 2003 Molecular and prognostic factors of prostate cancer. World J. Urol. 2003; 21(4):265-274
45. 2002 Quantitatively-determined urviving expression levels are of prognostic value in human gliomas J Clin Oncol. 2002; 20(4):1063-1068
46. 2002 The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res. 2002; 62(15):4307-4315
47. 2002 Insulin-like growth factor receptor I (IGFRI) mediates resistance to anti-epidermal growth factor receptor (EGFR) therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res. 2002; 62(1):200-207.
48. 2001 Prognostic and pathologic significance of protein expression profiling in human gliomas Clinical Cancer Research 2001; 7:2387-2395
49. 2001 Radiation Research Program, Radiation Oncology Sciences Program, NCI-HIH Int J Rad Onc Biol Phys 2001; 49(5): 1505-1516.
50. 2001 Translational Research Program Int J Radiat Oncol Biol Phys 2001; 51(3 suppl 2): 75-87.
51. 2000 Thymosin b15 predicts for distant failure for patients with clinically localized prostate cancer Urology 2000; 55(5):635-638.
52. 2000 Case records of the Massachusetts General Hospital. Case 18-2000. A 45-year-old woman with a thoracic mass and Pancoast’s syndrome. 1. New England Journal of Medicine 2000; 342(24): 1814-1821.
53. 1999 Ir-192 brachytherapy in the management of primary bile duct tumors. 1. Applied Radiology 1999; 28(4): 22-26.
54. 1999 Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant therapy. Annals of Surgery 1999; 230(1): 49-54.
55. 1999 Radiation therapy in the management of giant cell tumor of bone J. of Bone and Joint Surgery 1999; 81A: 1566-1573.
56. 1998 Loss of heterozygosity at chromosome 11q23 in SCC of the head and neck is associated with recurrent disease Clinical Cancer Research 1998; 4(11):2787-2793.
57. 1997 The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy-antrectomy gastroparesis Aliment. Pharmacol. Ther. 1997; 11(2):381-385
58. 1996 Cosegregation of familial pseudoobstruction and presence of digital arches in a large multigenerational pedigree Digestive Diseases and Sciences 1996; 41(7):1429-1433

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.